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There is a growing concern for overtreatment of localized prostate 
cancer because patients currently have earlier-stage disease than 
before the introduction of prostate-specific antigen (PSA) (1–3). 
Therefore, active surveillance (ie, deferred curative treatment for 
low-risk prostate cancer until the perceived disease progression) 
has  attracted  increasing  attention  (4,5).  Some  information  has 
been published on intermediate- and long-term outcomes of sur-
veillance from patients at single institutions (6–9), but, to the best 
of our knowledge, since the introduction of PSA, no results have 
been published from outcome studies of nationwide population-
based cohorts that include data on clinical stage, Gleason score, 
serum levels of PSA, and primary treatment.
After  a  median  follow-up  time  of  9  years,  the  European 
Randomized  Study  of  Screening  for  Prostate  Cancer  (ERSPC) 
reported lower prostate cancer–specific death rates (0.29%) in the 
screening arm than in the control arm (0.36%) (relative risk 
[RR] = 0.80, 95% confidence interval [CI] = 0.67 to 0.95) (10). 
There was considerable overdiagnosis and overtreatment in the 
screening arm because 1068 men had to be screened and 48 men 
had to undergo curative treatment to save one life. After 11 years 
of  follow-up,  the  Scandinavian  Prostate  Cancer  Group  study 
number 4 (SPCG-4), the only sufficiently large randomized clin-
ical trial on curative treatment for localized prostate cancer to date, 
reported a prostate cancer–specific mortality of 12.5% in the pros-
tatectomy arm and of 17.9% in the control arm (RR = 0.65, 95% 
CI = 0.45 to 0.94) (11). It should be noted that patients in the 
SPCG-4 trial had advanced prostate cancer by current standards 
and that watchful waiting, not active surveillance, was used in the 
control  arm.  Finally,  a  study  of  data  from  the  Surveillance, 
Epidemiology, and End Results (SEER) program in the United 
States reported a 10-year prostate cancer–specific mortality of 
8.3% (which was substantially lower than the value reported in the 
control arm of the SPCG-4 trial) among elderly patients with 
localized prostate cancer who were treated conservatively (12).
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= 0.3% to 1.4%) among the 1601 patients in the curative intent group. The 10-year risk of dying from competing 
causes was 19.2% (95% CI = 17.2% to 21.3%) in the surveillance group and 10.2% (95% CI = 9.0% to 11.4%) in 
the curative intent group.
  Conclusion  A 10-year prostate cancer–specific mortality of 2.4% among patients with low-risk prostate cancer in the surveillance 
group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease.
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The aim of this nationwide population-based cohort study was 
to assess prostate cancer mortality and risk of death from com-
peting causes in patients in the National Prostate Cancer Register 
(NPCR)  of  Sweden  Follow-up  Study  (hereafter  the  NPCR 
Follow-up Study) who had low- or intermediate-risk prostate can-
cer and who were treated with surveillance, radical prostatectomy, 
or  radiation  therapy  as  received  in  routine  clinical  practice  in 
Sweden from January 1, 1997, through December 31, 2002. Data 
were collected on clinical stage, Gleason score, serum PSA level, 
comorbidity, and socioeconomic status.
Participants and Methods
The Swedish Cancer Register and the NPCR of Sweden
Data on all cancer patients in Sweden must be submitted to the 
Swedish Cancer Register by law. The capture rate of this register 
has been estimated to be approximately 98% for solid tumors 
among patients younger than 75 years (13,14). Currently, 98% of 
all patients with newly diagnosed (ie, incident) prostate cancer in 
the Swedish Cancer Register are also registered in the NPCR, 
which contains data on TNM stage, tumor differentiation, serum 
PSA levels at the time of diagnosis, and primary treatment within 
6 months of the date of diagnosis (15–18). During the study 
period, conservative treatment (coded as “expectancy” in NPCR) 
included both active surveillance (ie, a strategy for delivering cura-
tive treatment when progression occurred) and watchful waiting 
(ie, a strategy for administering hormonal treatment when symp-
tomatic progression occurred).
Data Extraction for the Follow-up Study
The Follow-up Study was an observational study in the NPCR, 
with the aim of assessing outcome among patients with localized 
prostate cancer who were diagnosed after PSA testing had become 
prevalent in Sweden and for whom curative treatment may have 
been indicated. Inclusion criteria were registration in NPCR 
from January 1, 1997 (January 1, 1998, in one region), through 
December 31, 2002; age 70 years or younger at the date of diagno-
sis; local tumor stage T1–2 (in NPCR, clinical local tumor stage 
T2 is reported without any further subclassification into T2a, b, c); 
no signs of lymph node metastases (Nx or N0) or bone metastasis 
(Mx or M0); and serum PSA levels of less than 20 ng/mL (19). In 
total, 8304 patients fulfilled these criteria and 7960 accepted 
inclusion to the study (Figure 1). Verification of eligibility, data on 
treatment,  and  the  date  that  surveillance  was  terminated  were 
extracted from medical records by research nurses in each of six 
health-care regions in Sweden at a median time of 4 years after the 
date  of  diagnosis.  We  excluded  363  patients  who  had  received 
primary  hormonal  treatment,  and  because  we  wanted  to  study 
outcome in patients for whom surveillance is an accepted treat-
ment option, we further excluded 570 patients with poorly differ-
entiated tumors (Gleason score 8–10 or World Health Organization 
grade III). The final study set consisted of 6849 patients, including 
2686 who had low-risk prostate cancer (ie, clinical stage T1, 
Gleason score 2-6 or World Health Organisation grade I-II, 
and serum PSA level of <10 ng/mL). Treatment, which was sur-
veillance (n = 2021), or with curative intent including radical pros-
tatectomy (n = 3399) or radiation therapy (n = 1429), was assigned 
cONteXt AND cAVeAtS
Prior knowledge
Treatment of localized prostate cancer is controversial.
Study design
Retrospective study in a nationwide cohort of patients with localized 
prostate cancer who were 70 years or younger. These patients 
received surveillance (including active surveillance and watchful 
waiting) or treatment with curative intent (including radical prosta-
tectomy and radiation therapy). A subgroup of patients with low-
risk prostate cancer was also studied. The cumulative incidence of 
death from prostate cancer and competing causes was calculated.
Contribution
For the combination of low- and intermediate-risk prostate cancers, 
calculated  cumulative  10-year  prostate  cancer–  specific  mortality 
was 3.6% in the surveillance group and 2.7% in the curative intent 
group. For those with low-risk disease, the corresponding values 
were 2.4% in the surveillance group and 0.7% in the curative intent 
group. The 10-year risk of dying from competing causes was 19.2% 
in the surveillance group and 10.2% in the curative intent group.
Implications
The  low  10-year  prostate  cancer–specific  mortality  observed 
among patients with low-risk prostate cancer in the surveillance 
group indicates that surveillance may be a suitable treatment 
option for many patients with low-risk disease.
Limitations
The  observational  design  resulted  in  a  strong  selection  bias  in 
which a higher proportion of healthy patients with prostate cancer 
with adverse factors were assigned to radical prostatectomy than 
to surveillance. No information was available on tumor extent in 
core biopsy specimens, serum PSA levels after the date of diagnosis, 
or progression to metastatic disease. The median follow-up time 
was limited to 8.2 years.
From the Editors
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Figure 1. Identification and exclusion of men in the National Prostate 
Cancer  Register  (NPCR)  of  Sweden  Follow-up  Study.  The  complete 
database was defined as patients remaining after cleaning of the data 
set, before exclusion of patients who received hormonal treatment or 
had poorly differentiated tumors. Data cleaning is exclusion of men 
with  primary  treatments  other  than  surveillance,  prostatectomy,  or 
radiotherapy;  unknown  primary  treatment;  or  missing  data  on  PSA, 
grade, or stage. PSA = prostate-specific antigen; T1x = primary tumor 
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in clinical practice at the discretion of treating physician and 
patient. There was no uniform protocol that defined indications 
for surveillance, follow-up procedures, or criteria for initiation of 
deferred treatment in use at that time in Sweden.
By use of the unique 10-digit Swedish person identity number, 
we linked the NPCR Follow-up Study database to several other 
national databases. Complete follow-up regarding vital status from 
the date of diagnosis until December 31, 2008, was obtained by 
linkage  to  the  Swedish  Population  Register,  and  assessment  of 
cause of death was obtained by linkage to the Cause of Death 
Register up to December 31, 2007. Cause of death for patients 
who died from December 31, 2007, through December 31, 2008, 
was assessed by review of death certificates not yet entered into the 
Cause of Death Register by a research nurse. If there was uncer-
tainty,  then  a  urologist  was  consulted.  Death  was  attributed  to 
prostate cancer when prostate cancer was coded as “underlying 
cause  of  death.”  We  used  the  socioeconomic  status  from  the 
Census  Databases  of  1960–1990,  which  classified  patients  into 
lower socioeconomic status (including blue-collar and low-level 
white-collar  workers),  higher  socioeconomic  status  (including 
intermediate-  and  high-level  white-collar  workers  and  the 
self-employed), and unknown or missing socioeconomic status 
(20,21). We used the last socioeconomic status registered because 
many men had retired at the date of diagnosis. In the analysis, 
we  also  included  a  Charlson  comorbidity  index  constructed  on 
grouping of International Classification of Diseases (ICD) codes as 
described previously (22,23). We based the classification on data in 
the Patient Register, which contains data on discharge diagnoses, 
surgical procedures, and date of admission and discharge, which is 
updated annually and which has a capture rate for somatic inpa-
tient care of virtually 100% since 1987 (24). The Research Ethics 
Committee of Gothenburg University approved of the study in 
which an opt-out consent was distributed to all study subjects.
Statistical Analysis
The x
2 test and the t test were used to test the hypothesis that there 
was no difference in the distribution of the patient characteristics 
by treatment groups. All statistical tests were two-sided. The main 
endpoints in the analysis were death from prostate cancer, death 
from competing causes, and death from all causes. The endpoint 
for comparisons between observed and expected mortality was 
death from all causes, as estimated by use of population death rates 
from the entire Swedish population matched to the study popula-
tion by age and calendar year.
Cumulative incidence of mortality (25,26) and relative risk were 
used to measure associations with the main endpoints. The Pepe 
and Mori test (27) was used to test the hypothesis that there was no 
difference  in  the  cumulative  incidence  of  mortality  between 
treatment groups. The relative risk was estimated by use of the 
Cox proportional hazard model and competing-risks regression 
models according to the method of Fine and Gray (28). The 
proportional hazard assumption was tested with Schoenfeld resid-
uals, and we found no violation of the assumption of proportional 
hazards (29).
Because treatment effects may be larger among patients with 
intermediate-risk prostate cancer and because surveillance is par-
ticularly advocated for low-risk cancers (4–6,30), we also analyzed 
results by risk category. The low-risk category was defined as clin-
ical local stage T1a, b, or c and Gleason score 2-6 or World Health 
Organization  grade  I-II  and  a  serum  PSA  level  of  less  than   
10 ng/mL. The intermediate-risk category was defined as tumor stage   
T2 or Gleason score of 7 or serum PSA of 10 ng/mL or higher. 
The Stata statistical software was used for all statistical analyses 
(31). Adjustments in analyses were made for categories of comor-
bidity (Charlson index of 0–1 or ≥2), socioeconomic group (higher 
or lower), risk group (low or intermediate), and age as a continuous 
variable.
results
Among  the  6849  patients,  surveillance  was  started  in  2021 
(29.5%), radical prostatectomy was performed in 3399 (49.6%), 
and radiation therapy was delivered to 1429 (20.9%) (Table 1). 
A larger proportion of patients with low-risk tumors (40.4%) 
were treated with surveillance than patients with intermediate-
risk tumors (22.5%). After a median follow-up time of 4 years, 
692  (34%)  of  the  2021  patients  on  surveillance  had  received 
deferred  treatment,  which  was  radical  prostatectomy  for  277 
men, radiation therapy for 207 men, and hormonal therapy for 
208 men. More than 90% of all patients had a Charlson index of 
0 or 1 at the time of diagnosis. Surveillance was more common 
in  patients  with  high  comorbidity  and  was  initiated  in  1807 
(28.4%) of the 6347 patients with a Charlson index of 0–1 and 
in 220 (43.8%) of the 502 patients with a Charlson index 2 or 
higher. A slightly higher proportion of the 2563 patients with 
lower socioeconomic status received surveillance, 804 (31.4%), 
than  of  the  4125  patients  with  higher  socioeconomic  status, 
1134 (27.5%).
Death From Competing and All Causes
The median follow-up time was 8.2 years (interquartile range = 
7.1–9.7 years), and the numbers of patients who died during 
follow-up were 413 (20.4%) of the 2021 patients in the surveillance 
group, 286 (8.4%) of the 3399 patients in the radical prostatec-
tomy group, and 196 (13.7%) of the 1429 patients in the radiation 
therapy group (Table 2). The observed cumulated all-cause mor-
tality for all treatment groups combined was lower than expected 
(ie, in comparison with an age-matched background population). 
All-cause mortality in the surveillance group was similar to that of 
the background population, whereas all-cause mortality was lower 
than expected in the radiation therapy group and especially in the 
prostatectomy group (Figure 2). The 10-year cumulative risk of 
dying  of  competing  causes  differed  statistically  significantly  by 
treatment received and was 19.2% (95% CI = 17.2% to 21.3%) in 
the surveillance group, 10.2% (95% CI = 9.0% to 11.4%) in the 
curative intent group, including 8.5% (95% CI = 7.3% to 9.8%) in 
the prostatectomy group, and 14.2% (95% CI = 11.7% to 16.9%) 
in the radiation therapy group. These differences remained statis-
tically significant after adjustment for age, risk category, socioeco-
nomic status, and Charlson index (Table 3). In multivariable 
analyses  including  age,  risk  group,  treatment,  socioeconomic 
status, and Charlson index, death from competing causes was 
lower  among  patients  with  higher  socioeconomic  status  than 
among patients with lower socioeconomic status (RR = 0.77, 95% jnci.oxfordjournals.org    JNCI | Articles 953
CI = 0.66 to 0.90), and risk of death from competing causes was 
higher among patients with a Charlson index of 2 or higher than 
among patients with Charlson index of 0–1 (RR = 3.05, 95% CI = 
2.51 to 3.72).
Prostate Cancer–Specific Mortality
Death was attributed to prostate cancer in 58 (2.9%) of the 2021 
patients in the surveillance group, in 56 (1.7%) of the 3339 patients 
in the prostatectomy group, and in 40 (2.8%) of the 1429 patients 
Table 1. Recruitment period, age at diagnosis, tumor characteristics, comorbidity, and socioeconomic index for 6849 patients with 
prostate cancer: the National Prostate Cancer Register (NPCR) of Sweden Follow-up Study*
Characteristic
Surveillance  
group (n = 2021)
Radical prostatectomy  
group (n = 3399)
Radiation therapy  
group (n = 1429) Total cohort
Year of recruitment†, No. (%)
  1997–1998 569 (41.4) 584 (42.5) 221 (16.1) 1374
  1999–2000 667 (28.6) 1148 (49.3) 515 (22.1) 2330
  2000–2001 785 (25.0) 1667 (53.0) 693 (22.0) 3145
Age at diagnosis
  Age group, No. (%)
    <60 y 299 (16.3) 1224 (66.7) 313 (17.0) 1836
    60–64 y 519 (25.5) 1098 (53.9) 419 (20.6) 2036
    65–70 y 1203 (40.4) 1077 (36.2) 697 (23.4) 2977
    Mean, y (SD) 64.7 (4.6) 61.2 (5.3) 63.4 (4.9)
Clinical local T stage, No. (%)
  T1a 331 (83.0) 51 (12.8) 17 (4.3) 399
  T1b 91 (54.8) 46 (27.7) 29 (17.5) 166
  T1c 1021 (29.6) 1805 (52.3) 624 (18.1) 3450
  T2 578 (20.4) 1497 (52.8) 759 (26.8) 2834
Tumor differentiation, No. (%)
  Gleason score 2–6 or WHO I or II 1928 (32.8) 2798 (47.6) 1149 (19.6) 5875
  Gleason score 7 93 (9.5) 601 (61.7) 280 (28.7) 974
Serum PSA level
  Category, No. (%)
    0–4 ng/mL 422 (48.8) 343 (39.7) 100 (11.6) 865
    4–10 ng/mL 1049 (26.9) 2064 (52.9) 787 (20.2) 3900
    10–20 ng/mL 550 (26.4) 992 (47.6) 542 (26.0) 2084
    Mean, ng/mL (SD) 7.6 (4.4) 8.2 (3.9) 9.3 (4.2)
  Risk category‡, No. (%)
    Low 1085 (40.4) 1227 (45.7) 374 (13.9) 2686
    Intermediate 936 (22.5) 2172 (52.2) 1055 (25.3) 4163
Charlson comorbidity index, No. (%)
  0–1 1801 (28.4) 3233 (50.9) 1313 (20.7) 6347
  ≥2 220 (43.8) 166 (33.1) 116 (23.1) 502
Socioeconomic index, No. (%)
  Low 804 (31.4) 1199 (46.8) 560 (21.8) 2563
  High 1134 (27.5) 2152 (52.2) 839 (20.3) 4125
  Undefined or missing 83 (51.6) 48 (29.8) 30 (18.6) 161
*  P for difference between treatment groups for all variables was less than .001, the x2 test was used for categorical variables and the t test for continuous 
variables. All statistical tests are two-sided. PSA = prostate-specific antigen; WHO = World Health Organization.
†  In 1997, five of the six regions in Sweden participated (South, South-East, Western, Uppsala–Örebro, and Northern regions). From 1998 through 2002,  
all six regions in Sweden, including Stockholm–Gotland, participated in the NPCR Follow-up Study.
‡  The low-risk category was defined as tumor stage of T1a, b, or c; Gleason score 2-6 or WHO grade of I-II; and a serum PSA level of less than 10 ng/mL.  
The intermediate-risk category was defined as a Gleason score of 7 or a tumor stage of T2 or a serum PSA level of 10 ng/mL or higher.
Table 2. Time at risk and cause of death according to risk category and treatment group among 6849 patients with prostate cancer in 
the National Prostate Cancer Register (NPCR) of Sweden Follow-up Study
Time at risk, cause of death, and risk category
Surveillance group  
(n = 2021)
Radical prostatectomy  
group (n = 3399)
Radiation therapy   
group (n = 1429)
Man-years at risk 15 970 27 118 11 173
No. of deaths from all causes (%) 413 (20.4) 286 (8.4) 196 (13.7)
No. of deaths from competing causes* (%) 355 (17.6) 230 (6.8) 156 (10.9)
No. of prostate cancer–specific deaths† (%) 58 (2.9) 56 (1.7) 40 (2.8)
  Low-risk category 14 (1.3) 4 (0.3) 5 (1.3)
  Intermediate-risk category 44 (4.7) 52 (2.4) 35 (3.3)
*  Cause of death was missing for 27 patients.
†  The low-risk category was defined as tumor stage of T1a, b, or c; Gleason score 2-6 or World Health Organization grade of I-II; and serum prostate-specific antigen (PSA) 
level of less than 10 ng/mL. The intermediate-risk category was defined as Gleason score of 7 or tumor stage T2 or serum PSA level of 10 ng/mL or higher.954   Articles | JNCI  Vol. 102, Issue 13  |  July 7, 2010
in the radiation therapy group (Table 2). The calculated cumulated 
prostate cancer–specific mortality after 10 years of follow-up was 
3.6% (95% CI = 2.7% to 4.8%) in the surveillance group and 2.7% 
(95% CI = 2.1% to 3.4%) in the curative intent groups, including 
the prostatectomy group (2.4%, 95% CI = 1.8% to 3.3%) and the 
radiation therapy group (3.3%, 95% CI = 2.5% to 5.7%) (Table 3 
and Figure 3). Among those with low-risk disease, prostate cancer– 
specific mortality was 2.4% (95% CI = 1.2% to 4.1%) in the 
surveillance group and 0.7% (95% CI = 0.3% to 1.4%) in the 
curative intent groups, including the prostatectomy group (0.4%, 
95% CI = 0.13% to 0.97%) and the radiation therapy group (1.8%, 
95% CI = 0.65% to 4.0%). Among those in the intermediate-risk 
category, prostate cancer–specific mortality was more than twice as 
high as for those in the low-risk category: 5.2% (95% CI = 3.7% 
to 6.9%) in the surveillance group, 3.4% (95% CI = 2.5% to 4.7%) 
in the prostatectomy group, and 3.8% (95% CI = 2.6% to 5.4%) 
in the radiation therapy group.
After adjustment for risk category, Charlson index, and socio-
economic status, there was a lower risk of prostate cancer–specific 
mortality among those in the prostatectomy group than among those 
in the surveillance group (RR = 0.49, 95% CI = 0.34 to 0.71), among 
those in the radiation therapy group than among those in the surveil-
lance group (RR = 0.70, 95% CI = 0.45 to 1.09), and among those in 
the prostatectomy group than among those in the radiation therapy 
group (RR = 0.72, 95% CI = 0.47 to 1.11). In a multivariable analysis, 
prostate  cancer–specific  mortality  was  lower  among  patients  with 
higher socioeconomic status than those with lower socioeconomic 
status (RR = 0.69, 95% CI = 0.50 to 0.95), and prostate cancer– 
specific mortality was also lower among those with high comorbidity 
(for those with a Charlson index of ≥2 compared with those with a 
Charlson index of 0–1, RR = 0.24, 95% CI = 0.08 to 0.75).
Discussion
In this nationwide population-based cohort of 6849 patients with 
low- or intermediate-risk prostate cancer in Sweden, risk of prostate 
cancer–specific death was low at up to 8.2 years after diagnosis 
regardless of treatment strategy, with only 154 (17%) of the 895 
deaths  being  attributed  to  prostate  cancer.  Cumulative  10-year 
prostate cancer–specific mortality was 3.6% for patients in the 
surveillance group and 2.7% for those in the curative intent 
groups. Among the group of 2686 patients with low-risk prostate 
cancer, the corresponding prostate cancer–specific mortality was 
2.4% for patients in the surveillance group and 0.7% for those in 
the curative intent groups.
Death From Competing Causes and All Causes, 
Confounding by Indication and Selection Bias
All-cause mortality in the full cohort was lower than expected, in-
dicating that, in clinical practice, there is a selection of healthy men 
for PSA testing and further work-up, leading to a diagnosis of 
localized prostate cancer. There was a much higher percentage of 
death from competing causes among patients in the surveillance 
group (17.6%) than among patients in the prostatectomy group 
(6.8%) or in the radiation therapy group (10.9%). Thus, patients 
with a short life expectancy were more often selected for surveil-
lance than for surgery or radiation therapy. We tried to adjust for 
this selection bias by including into analysis indices indicative of 
socioeconomic status and comorbidity, which are known to be 
associated with life expectancy. However, when we adjusted the 
model for comorbidity and socioeconomic status, risk estimates of 
death from competing and all causes were not materially different 
from unadjusted estimates. Thus, adjustments for these indices 
were not sufficient to compensate for the confounding by indica-
tion to treatment caused by treatment selection in clinical patient 
management in our cohort. Giordano et al. (32) similarly tried to 
compensate for confounding in a study of localized prostate cancer 
that used data in SEER and Medicare files, but also they found that 
a large difference in all-cause mortality, mainly from competing 
causes of death, still remained after adjustments for year of diagno-
sis, age, race, urban residence, marital status, income, education, 
SEER region, tumor size, tumor grade, and comorbidity score. 
Figure 2. Observed and expected all-cause mortality for patients in the National Prostate Cancer Register (NPCR) of Sweden Follow-up Study.   
A) Patients who were treated with surveillance. B) Patients who were treated with radical prostatectomy. C) Patients who were treated with   
radiation therapy. Error bars = 95% confidence intervals.jnci.oxfordjournals.org    JNCI | Articles 955
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Both the study by Giordano et al. and the NPCR Follow-up Study 
show that adjustment for comorbidity and socioeconomic status by 
use of register-derived data cannot compensate for the bias and 
confounding that occurs in observational studies that are based on 
routine clinical management. Thus, all-cause mortality is not a 
valid  endpoint  in  evaluating  treatment  effects  in  observational 
studies of localized prostate cancer because most patients with 
localized prostate cancer die from competing causes and because 
the confounding is strongly related to competing causes of death, 
relative survival is likewise not a useful measure.
Prostate Cancer–Specific Mortality Among Patients on 
Surveillance and Patients on Curative Treatment
Fewer patients with intermediate-risk tumors received surveillance 
(n = 936) than curative treatment (n = 3227), and other adverse 
tumor factors that were not possible to study in our analyses (eg, 
tumor extent on biopsy examination) also appear to have been less 
adverse among those on surveillance. Thus, there was also con-
founding by indication for tumor-related factors, but tumor factors 
had a weaker effect on all-cause mortality than factors related to 
overall health. Furthermore, 484 (24%) of the 2021 patients in the 
surveillance group subsequently received curative treatment during 
follow-up. Despite these biases in overall health, tumor-related 
factors, and initiation of deferred treatment that would decrease 
the difference in prostate cancer–specific mortality between those 
in  the  surveillance  group  and  those  in  the  curative  treatment 
group, the risk of calculated cumulative prostate cancer–specific 
death was statistically significantly lower among patients in the 
prostatectomy  group  than  among  patients  in  the  surveillance 
group (RR = 0.49, 95% CI = 0.34 to 0.71), but the difference in 
absolute risk between the groups was still very modest (1.2%) after 
10 years of follow-up. The difference is in the same direction and 
in same order of magnitude as that observed in the randomized 
SPCG-4 trial (RR = 0.65, 95% CI = 0.45 to 0.94) (11); however, 
we acknowledge that the NPCR Follow-up Study was not well 
suited  to  quantify  the  difference  in  effect  of  various  treatment 
strategies on prostate cancer–specific mortality because of con-
founding that was related to overall health and prostate cancer 
aggressiveness.
Comparison with Published Observational Studies on 
Surveillance
Some single-institution studies (6–9) of active surveillance for 
localized prostate cancer have reported favorable outcome. The 
inclusion criteria for these series have generally included well-
differentiated tumors as reflected by a Gleason score of 6 or lower, 
clinical local stage of T2 or lower, serum PSA levels of less than 
10 ng/mL, PSA density of less than 0.2 ng/mL per cm
3, tumor extent 
on core biopsy examination that was limited to a maximum of two 
cores involved, and follow-up with PSA testing every 3–6 months 
and re-biopsy examination at 1–2 years after diagnosis. These 
studies (6–9) have also reported low progression rates, especially, 
Klotz (6,8) observed a prostate cancer–specific mortality of 1% 
among 299 patients with low-risk prostate cancer who had been 
followed for a median time of 7 years compared with the 10-year 
prostate cancer–specific mortality of 2.4% among 1085 patients 
with low-risk tumors (ie, Gleason score 2-6, T1 tumors, and   
serum PSA level of <10 ng/mL) in the NPCR Follow-up Study. 
Many of the men on surveillance in the NPCR Follow-up cohort 
would  not  have  fulfilled  the  inclusion  criteria  in  contemporary 
surveillance protocols and were followed less rigorously. Thus, we 
expect that prostate cancer–specific mortality among patients with 
low-risk  prostate  cancer  on  contemporary  active  surveillance 
protocols will be lower than such mortality that we reported in this 
study.
In contrast to the NPCR Follow-up Study and the observa-
tional studies (6–9) of surveillance that included patients with 
low-risk tumors and favorable outcome, which mirrors the current 
trend toward earlier stage at diagnosis (3), tumor characteristics 
were much more adverse in the randomized SPCG-4 trial (11) in 
Figure 3. Prostate cancer–specific mortality for patients who were treated with surveillance, radiation therapy, or radical prostatectomy in the 
National Prostate Cancer Register (NPCR) of Sweden Follow-up Study.A) Combination of low- and intermediate-risk patients. B) Low-risk patients. C) 
Intermediate-risk patients. Error bars = 95% confidence intervals. RP = radical prostatectomy; RT = radiation therapy; Surv = surveillance.jnci.oxfordjournals.org    JNCI | Articles 957
1989–1999 (ie, approximately 10% of the patients had stage T1c 
tumors) than those in the NPCR Follow-up cohort (ie, 50% of 
patients had stage T1c tumors). Prostate cancer–specific mortality 
was five times higher in SPCG-4 than in the NPCR Follow-up 
Study. For example, the absolute risk of prostate cancer death in 
the prostatectomy group was 12.5% in the SPCG-4 trial compared 
with 2.4% in the NPCR Follow-up cohort, and it was 17.9% in the 
SPCG-4 control group compared with 3.6% in the surveillance 
group in the NPCR cohort.
In the recent SEER study (12) on outcomes after conservative 
treatment of elderly US patients diagnosed with prostate cancer in 
1992–2002 who had a mean age at diagnosis of 78 years and of 
whom 40% had received primary androgen deprivation therapy, 
the 10-year prostate cancer–specific mortality was 8% among the 
222 patients with well-differentiated tumors (Gleason scores 2–4) 
and 9% among the 1088 patients with moderately differentiated 
tumors (Gleason scores 5–7) with unknown serum PSA levels. In 
total, 60% of these elderly patients died during follow-up, showing 
that overall health as well as age were quite different from cur-
rently  diagnosed  prostate  cancer  patients  contemplating  active 
surveillance.
Two systematic reviews (33,34) on the outcome after external 
beam radiation therapy in patients with localized prostate cancer 
reported a wide range of outcomes. Low mortality rates have been 
reported after high-dose radiation therapy (35). However, in the 
NPCR Follow-up cohort, we did not have detailed data on the 
radiation doses, a higher proportion of patients who received radi-
ation therapy had intermediate-risk tumors than patients on sur-
veillance  or  who  received  surgery,  and  prostate  cancer–specific 
mortality was not statistically significantly lower in patients who 
received radiation therapy than in patients on surveillance.
This study had several strengths. The NPCR Follow-up Study 
was population based and included men from all types of medical 
facilities in the entire nation of Sweden. On the basis of a 98% 
capture rate of the Swedish Cancer Register of all prostate cancer 
patient data, a 98% capture rate for the NPCR of Sweden vs the 
Cancer  Register,  and  a  94%  capture  rate  for  the  Follow-up 
Study, we included 90% of all patients in Sweden aged 70 years or 
younger with a low- or intermediate-risk prostate cancer who were 
diagnosed from January 1, 1997, through December 31, 2002. We 
had data on tumor stage, differentiation, and serum PSA level and 
primary treatment from NPCR. These data were verified, and 
termination  of  surveillance  and  initiation  of  deferred  treatment 
was assessed in a review of medical records. We also had access 
to data on socioeconomic status and comorbidity by linkage to 
other national registries. The reliability of death certificates in the 
Swedish Cause of Death Register for a correct assessment of cause 
of death among patients with prostate cancer has been shown to be 
rather high; 88% of deaths that had been attributed to prostate 
cancer among patients with localized disease were found to be 
attributed to prostate cancer in a reexamination of medical records 
(36). Thus, the results from the NPCR Follow-up Study popula-
tion appear to be representative of contemporary patient outcomes 
in Sweden as obtained in clinical practice.
This study had several limitations. The observational design 
resulted in a strong selection bias in which a higher proportion of 
healthy  patients  with  prostate  cancer  with  adverse  factors  were 
assigned to radical prostatectomy than to surveillance. No infor-
mation was available for the NPCR Follow-up cohort on tumor 
extent in core biopsy specimens, serum PSA levels after the date of 
diagnosis,  or  progression  to  metastatic  disease.  The  median 
follow-up time was limited to 8.2 years, and because most patients 
currently diagnosed with localized prostate cancer are aged 60–70 
years and have a life expectancy of more than 15 years, longer 
follow-up is needed.
In conclusion, with a 10-year prostate cancer–specific mortality 
of less than 3% for patients with low-risk prostate cancer on 
surveillance, this strategy appears to be suitable for many of these 
men.  However,  additional  follow-up  is  required  for  conclusive 
evaluation of surveillance as treatment strategy in prostate cancer.
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